

FAIRVIEW ADVISORS COMPLETES SALE OF PREFERRED STOCK FOR ALTOR BIOSCIENCE CORPORATION

Naples, Florida and San Francisco, California, November, 2005 — Fairview Advisors, LLC, an investment banking firm led by seasoned executives, completed the sale of Altor BioScience Corporation Series B-1 Preferred Stock to Sanderling, a leading biotech venture capitalist.

“Altor is very pleased with the results of this financing,” said Dr. Hing Wong, Altor’s Chief Executive Officer. Dr. Wong commented further, “FairView introduced us to an important new investor and leading biomedical venture capitalist and this equity financing marks another important milestone in Altor’s continued successful development.” According to FairView Advisors’, John Taylor, “We were very pleased to work with Dr. Wong and Altor BioScience Corporation on this transaction.” “Altor is an excellent and exciting company and Sanderling is a leading biomedical venture capitalist.” Matching them up and concluding this financing just made a lot of sense.” Taylor added, “FairView is very comfortable working in this marketplace and looks forward to providing its services and adding value to many other leading biotech companies.”

About FairView Advisors

FairView Advisors specializes in Mergers and Acquisitions, debt and private equity financing as well as strategic advisory work for companies in select industries, including, biomedical and health care, financial services, information technology, telecom and wireless as well as sports and media. Led by a seasoned management team with significant financial and operating experience, FairView Advisors utilizes a team approach to assist its clients in defining their issues and needs, and then executing a transaction to achieve the client’s desired results. The company’s senior management team has completed numerous transactions in their targeted industries including M&A, capital raising, and strategic advisory work and has individually grown firms to multi-billion market capitalizations. The company is headquartered in Naples, Florida and maintains offices in New Jersey, Pittsburg and Northern California. FairView’s website is www.fairviewadvisors.com.

About Sanderling

Founded in 1979, Sanderling is among the oldest investment firms dedicated to building new biomedical companies. Sanderling's unique approach combines a specialized investment focus with active management and long-term commitment to ensure the highest rates-of-return for both its entrepreneurs and investors. Since its inception, Sanderling has supported over 40 biomedical companies from very early stages through commercial development, earning consistently high rates-of-return on its venture investments. For more information about Sanderling, visit their website at www.sanderling.com.

About Altor BioScience Corporation

Altor BioScience Corporation is a biopharmaceutical company developing a new class of therapeutic products for the treatment of cancer, viral infections and autoimmune diseases. Altor was launched in August 2002 as a spin-off of Sunol Molecular Corporation. With extensive experience in the biotechnology industry, Altor's scientific and management team has the knowledge required to take products from concept to clinical testing. Several of Altor's product candidates are already in the advanced stages of testing necessary to initiate human clinical trials. For more information about Altor, visit their website at www.althorbioscience.com.